The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Orphan nuclear receptors—new ligands and new possibilities: Figure 1.
Open accessAbstract
Nuclear hormone receptors comprise a large superfamily of ligand-modulated transcription factors that, in part, mediate response to steroids, retinoids and thyroid hormones and play key roles in development and body physiology (for review, see Beato et al. 1995; Kastner et al. 1995; Mangelsdorf and Evans 1995; Mangelsdorf et al. 1995; Enmark and Gustaffson 1996; Willy and Mangelsdorf 1998). Ten years ago the first orphan nuclear receptors were isolated, raising the first portents toward a new era in physiology (Giguere et al. 1988). Although structurally related to the known receptors, no physiological ligands or activators were known for these orphan receptors which are more numerous (19 families) than receptors with known ligands (10 families). Orphan receptors represent a diverse and ancient component of the nuclear receptor superfamily, being found in nearly all animal species examined. Orphan nuclear receptors provide a unique and, until recently, largely untapped resource to uncover regulatory systems that impact on both health and human disease. Shortly after their isolation, strategies were devised to identify orphan ligands using the receptor as a screening target. This process, referred to as ‘reverse endocrinology,’ has led previously to the identification of ligands for RXRs [9-cis retinoic acid receptors (RARs), a.k.a. retinoid X receptors], PPARs (peroxisome proliferator-activated receptors), FXRs (farnesoid X receptors), and LXRs (liver X receptors). In a review eight years ago, Bert O’Malley predicted that the field of orphan receptors would provide much excitement for the future (O’Malley 1990). The promise of orphan receptors is that they provide an opportunity to identify not only novel ligands but perhaps unsuspected classes of ligands and potentially new principles of physiology. Because all known receptors are important in the treatment of human disease, their signaling pathways have direct implications for drug discovery. The purpose of this review is to highlight advances made on four new orphan receptor-mediated signaling pathways [BXR (benzoate X receptor), CARb (constitutive androstane receptor), PXR (pregnane X receptor), and SXR (steroid and Xenobiotic receptor)] with brief updates on recent progress for FXR, PPARg, and LXRa. To restrict the scope of the review, we will focus only on orphans forming heterodimers with RXR and studies that have been reported in the last year. We will emphasize what has been learned about the nature of the ligands, new modes of regulation, insights into physiology, and potential new drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Self-citationStimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158
Self-citationPPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81574-3 · Cited by 1,860
Self-citationSteroid hormone receptors: Many Actors in search of a plot
Beato, M., Herrlich, P., & Schütz, G. (1995) · Cell · doi:10.1016/0092-8674(95)90201-5 · Cited by 1,823
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Self-citationKliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Self-citationAn oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E., & Mangelsdorf, D. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81432-4 · Cited by 1,436
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233 · cited 1×
“Recently, LXRs were shown to be activated by naturally-occurring oxidized cholesterol derivatives such as 22(R) and 24(S) hydroxycholesterol and 24(S),25-epoxycholesterol (Janowski et al. 1996; Forman et al. 1997; Lehmann et al. 1997).”
BackgroundIdentification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Self-citationLXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
Self-citationNonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life?
Kastner, P., Mark, M., & Chambon, P. (1995) · Cell · doi:10.1016/0092-8674(95)90202-3 · Cited by 995
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
SXR, a novel steroid and xenobioticsensing nuclear receptor
Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.20.3195 · Cited by 919
Self-citationChawla, A., Schwarz, E. J., Dimaculangan, D. D., & Lazar, M. A. (1994) · Endocrinology · doi:10.1210/en.135.2.798 · Cited by 873
Identification of a new class of steroid hormone receptors
Giguère, V., Yang, N., Segui, P., & Evans, R. M. (1988) · Nature · doi:10.1038/331091a0 · Cited by 867
Self-citationTerminal Differentiation of Human Breast Cancer through PPARγ
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 851
Self-citationUnique response pathways are established by allosteric interactions among nuclear hormone receptors
Forman, B. M., Umesono, K., Chen, J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90075-6 · Cited by 624
Self-citationSensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
Mukherjee, R., Davies, P. J. A., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., et al. (1997) · Nature · doi:10.1038/386407a0 · Cited by 605
MINIREVIEW: The Steroid Receptor Superfamily: More Excitement Predicted for the Future
O'Malley, B. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-3-363 · Cited by 485
Androstane metabolites bind to and deactivate the nuclear receptor CAR-β
Forman, B. M., Tzameli, I., Choi, H.-S., Chen, J., Simha, D., Seol, W., Evans, R. M., & Moore, D. D. (1998) · Nature · doi:10.1038/26996 · Cited by 476
Self-citationRegulation of retinoid signalling by receptor polarity and allosteric control of ligand binding
Kurokawa, R., DiRenzo, J., Boehm, M., Sugarman, J., Gloss, B., Rosenfeld, M. G., Heyman, R. A., & Glass, C. K. (1994) · Nature · doi:10.1038/371528a0 · Cited by 429
Human cytochromes P450: problems and prospects
Gonzalez, F. J. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90107-h · Cited by 363
Gonzalez, F. J., Song, B. J., & Hardwick, J. P. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.8.2969 · Cited by 296
Forman, B. M., Ruan, B., Chen, J., Schroepfer, G. J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10588 · Cited by 280
Self-citationHormones and Resistance: Part 1 and Part 2
Selye, H. (1971) · Springer eBooks · doi:10.1007/978-3-642-65192-2 · Cited by 220
Orphan nuclear receptors--the first eight years
Enmark, E. (1996) · Molecular Endocrinology · doi:10.1210/me.10.11.1293 · Cited by 212
CHANGES IN CORTISOL METABOLISM FOLLOWING RIFAMPICIN THERAPY
Edwards, O., Galley, J. M., Courtenay-Evans, R. J., Hunter, J., & Tait, A. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91876-5 · Cited by 209
Blumberg, B., Mangelsdorf, D. J., Dyck, J. A., Bittner, D., Evans, R. M., & Robertis, E. M. D. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2321 · Cited by 157
Self-citationSelye, H. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600600102 · Cited by 143
PPARγ in Monocytes: Less Pain, Any Gain?
Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81567-6 · Cited by 135
The phantom ligand effect: allosteric control of transcription by the retinoid X receptor.Preprint
Schulman, I. G., Li, C., Schwabe, J. W. R., & Evans, R. M. (1997) · Genes & Development · doi:10.1101/gad.11.3.299 · Cited by 127
Self-citationKyriazopoulou, V. E., PARPAROUSI, O., & Vagenakis, A. G. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-6-1204 · Cited by 108
Activation of the orphan receptor RIP14 by retinoids
Zavacki, A. M., Lehmann, J. M., Seol, W., Willson, T. M., Kliewer, S. A., & Moore, D. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.7909 · Cited by 88
Burger, H.-J., Schuetz, J. D., Schuetz, E. G., & Guzelian, P. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2145 · Cited by 82
Blumberg, B., Kang, H., Bolado, J., Chen, H., Craig, A. G., Moreno, T. A., Umesono, K., Perlmann, T., Robertis, E. M. D., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.9.1269 · Cited by 73
Self-citationWilly, P. J., & Mangelsdorf, D. J. (1998) · Elsevier eBooks · doi:10.1016/b978-012312411-1/50011-1 · Cited by 50
Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy.
Kyriazopoulou, V. E., & Vagenakis, A. G. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.1.1619024 · Cited by 40
Smith, D. P., Mason, C., Jones, E. A., & Old, R. W. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.1.66 · Cited by 33
Misdiagnosis of Cushing's Syndrome in a Patient Receiving Rifampicin Therapy for Tuberculosis
Terzolo, M., Borretta, G., Alì, A., Cesario, F., Magro, G. G., Boccuzzi, A., Reimondo, G., & Angeli, A. (1995) · Hormone and Metabolic Research · doi:10.1055/s-2007-979927 · Cited by 17
The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing’s syndrome
Zawawi, T. H., Al-Hadramy, M. S., & Abdelwahab, S. M. (1996) · Irish Journal of Medical Science (1971 -) · doi:10.1007/bf02943098 · Cited by 9
Cited by
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Metadata
- Authors
- Blumberg, B., & Evans, R. M.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1998-10-15
- Volume
- 12
- Issue
- 20
- Pages
- 3149-3155
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W1999580573
- Cited by
- 301
- References
- 47
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.